Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also ...

U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...

Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Generalists, on the other hand, view Novo as leading in sales force image and being on par with Lilly in other key aspects of image. Merck followed as a close third among PCPs in all aspects of image.